ProKidney (PROK) Competitors $0.89 -0.19 (-18.00%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. NTLA, SYRE, ZYME, RCUS, NRIX, CMRX, CDMO, ELVN, OCS, and GYREShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Zymeworks (ZYME), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Chimerix (CMRX), Avid Bioservices (CDMO), Enliven Therapeutics (ELVN), Oculis (OCS), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Intellia Therapeutics Spyre Therapeutics Zymeworks Arcus Biosciences Nurix Therapeutics Chimerix Avid Bioservices Enliven Therapeutics Oculis Gyre Therapeutics ProKidney (NASDAQ:PROK) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do analysts rate PROK or NTLA? ProKidney currently has a consensus price target of $5.00, suggesting a potential upside of 464.59%. Intellia Therapeutics has a consensus price target of $36.68, suggesting a potential upside of 313.58%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Is PROK or NTLA more profitable? ProKidney's return on equity of 0.00% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Intellia Therapeutics N/A -49.34%-40.27% Do insiders and institutionals believe in PROK or NTLA? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, PROK or NTLA? ProKidney has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$76K3,410.70-$35.47M-$0.63-1.41Intellia Therapeutics$57.88M15.86-$481.19M-$5.25-1.69 Does the media prefer PROK or NTLA? In the previous week, Intellia Therapeutics had 8 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Intellia Therapeutics and 3 mentions for ProKidney. ProKidney's average media sentiment score of 1.45 beat Intellia Therapeutics' score of 1.10 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, PROK or NTLA? ProKidney has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Does the MarketBeat Community favor PROK or NTLA? Intellia Therapeutics received 436 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 68.94% of users gave Intellia Therapeutics an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% Intellia TherapeuticsOutperform Votes44468.94% Underperform Votes20031.06% SummaryProKidney and Intellia Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.21M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.6130.4222.4218.48Price / Sales3,410.70498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book-0.183.206.774.25Net Income-$35.47M-$72.35M$3.22B$248.23M7 Day Performance-2.69%3.57%3.26%3.29%1 Month Performance-2.68%0.17%0.02%2.42%1 Year Performance-57.11%-21.21%18.01%5.54% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney2.4919 of 5 stars$0.89-18.0%$5.00+464.6%-57.1%$316.11M$76,000.00-1.613Positive NewsNTLAIntellia Therapeutics4.4678 of 5 stars$7.92+9.5%$36.68+363.2%-58.6%$819.86M$57.88M-1.46600Upcoming EarningsHigh Trading VolumeSYRESpyre Therapeutics1.7938 of 5 stars$13.57+7.1%$49.57+265.3%-53.9%$817.95M$890,000.00-1.82100Upcoming EarningsPositive NewsZYMEZymeworks2.7711 of 5 stars$11.75+1.9%$21.00+78.7%+51.6%$817.53M$76.30M-7.83460Upcoming EarningsPositive NewsRCUSArcus Biosciences2.0512 of 5 stars$7.68-2.5%$30.25+293.9%-42.6%$807.46M$258M-2.44500Upcoming EarningsPositive NewsGap DownNRIXNurix Therapeutics1.9428 of 5 stars$10.55+3.0%$30.44+188.6%-4.1%$804.29M$56.42M-3.65300Analyst ForecastPositive NewsGap DownCMRXChimerix3.0303 of 5 stars$8.55-0.1%$8.53-0.1%N/A$801.56M$212,000.00-9.0990CDMOAvid Bioservices0.746 of 5 stars$12.50+0.1%$12.25-2.0%+63.8%$799.18M$139.91M-5.23320High Trading VolumeELVNEnliven Therapeutics2.2569 of 5 stars$16.22-1.9%$40.33+148.7%+8.9%$794.85MN/A-8.5450News CoveragePositive NewsGap DownOCSOculis2.8556 of 5 stars$18.12-0.8%$30.25+66.9%+33.1%$791.16M$980,000.00-9.392Short Interest ↓News CoverageGYREGyre Therapeutics0.0864 of 5 stars$8.40-5.4%N/A-37.4%$786.34M$105.76M168.0040Upcoming Earnings Related Companies and Tools Related Companies NTLA Alternatives SYRE Alternatives ZYME Alternatives RCUS Alternatives NRIX Alternatives CMRX Alternatives CDMO Alternatives ELVN Alternatives OCS Alternatives GYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PROK Stock Free PROK Stock Alerts